What is Chardan Capital’s Estimate for ALUR FY2024 Earnings?

Allurion Technologies Inc. (NYSE:ALUR) – Equities researchers at Chardan Capital lifted their FY2024 earnings estimates for Allurion Technologies in a research report issued on Sunday, January 12th. Chardan Capital analyst K. Nakae now expects that the company will post earnings of ($7.63) per share for the year, up from their prior estimate of ($7.75). Chardan Capital has a “Neutral” rating on the stock. The consensus estimate for Allurion Technologies’ current full-year earnings is ($10.12) per share. Chardan Capital also issued estimates for Allurion Technologies’ FY2025 earnings at ($4.82) EPS.

Separately, TD Cowen assumed coverage on shares of Allurion Technologies in a report on Wednesday, October 2nd. They issued a “buy” rating and a $50.00 price objective for the company. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $71.88.

Allurion Technologies Stock Performance

ALUR opened at $3.10 on Wednesday. Allurion Technologies has a fifty-two week low of $2.72 and a fifty-two week high of $98.75. The company has a fifty day moving average of $9.37 and a two-hundred day moving average of $15.70. The stock has a market capitalization of $8.03 million, a price-to-earnings ratio of -0.26 and a beta of -0.62.

Institutional Trading of Allurion Technologies

An institutional investor recently bought a new position in Allurion Technologies stock. CVI Holdings LLC bought a new position in shares of Allurion Technologies Inc. (NYSE:ALUR) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 521,440 shares of the company’s stock, valued at approximately $520,000. Allurion Technologies makes up approximately 0.5% of CVI Holdings LLC’s investment portfolio, making the stock its 28th largest position. CVI Holdings LLC owned about 1.09% of Allurion Technologies as of its most recent filing with the Securities and Exchange Commission (SEC). 21.39% of the stock is currently owned by institutional investors.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.